John M. Burke
About
John M. Burke is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics.
According to data from OpenAlex, John M. Burke has authored 177 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Pathology and Forensic Medicine, 62 papers in Oncology and 59 papers in Genetics. Recurrent topics in John M. Burke's work include Lymphoma Diagnosis and Treatment (76 papers), Chronic Lymphocytic Leukemia Research (50 papers) and Monoclonal and Polyclonal Antibodies Research (27 papers). John M. Burke is often cited by papers focused on Lymphoma Diagnosis and Treatment (76 papers), Chronic Lymphocytic Leukemia Research (50 papers) and Monoclonal and Polyclonal Antibodies Research (27 papers). John M. Burke collaborates with scholars based in United States, Australia and Canada. John M. Burke's co-authors include Kathryn S. Kolibaba, Ian W. Flinn, Brad S. Kahl, Samar Issa, David MacDonald, David Simpson, Peter Wood, Tim E. Hawkins, Richard van der Jagt and Doreen M. Hallman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
John M. Burke
166 papers receiving 3.0k citations
Hit Papers
Peers
John M. Burke
Sandra Eloranta Sweden
Carrie A. Thompson United States
Grant W. Cannon United States
María A. López-Olivo United States
James D. Bearden United States
Helen K. Chew United States
Soo‐Mee Bang South Korea
Gerard Vreugdenhil Netherlands
Marc Botteman United States
Laura Giordano Italy
Citations per year, relative to John M. Burke John M. Burke (= 1×)
peers
Sandra Eloranta
Countries citing papers authored by John M. Burke
Since
Specialization
Citations
This map shows the geographic impact of John M. Burke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Burke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Burke more than expected).
Fields of papers citing papers by John M. Burke
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by John M. Burke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Burke. The network helps show where John M. Burke may publish in the future.
Co-authorship network of co-authors of John M. Burke
This figure shows the co-authorship network connecting the top 25 collaborators of John M. Burke. A scholar is included among the top collaborators of John M. Burke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John M. Burke. John M. Burke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sharman, Jeff P., Aung M. Tun, José C. Villasboas, et al.. (2025). Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study. Blood. 146(Supplement 1). 62–62.
2.
Schenkel, Caroline, Laura A. Levit, M. Kelsey Kirkwood, et al.. (2025). State of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023. PubMed. 2(2). e2400010–e2400010.
3.
Shadman, Mazyar, John M. Burke, Jennifer L. Cultrera, et al.. (2025). Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results. Blood Advances. 9(16). 4100–4110.
4.
Phillips, Tycel, et al.. (2023). Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial. Leukemia & lymphoma. 64(5). 1017–1025.
5.
Morschhauser, Franck, Katerina Hatzi, Georg Lenz, et al.. (2023). IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCY. Hematological Oncology. 41(S2). 223–225.
6.
El‐Mallawany, Nader Kim, Lisa Giulino‐Roth, John M. Burke, Michelle L. Hermiston, & Carl E. Allen. (2023). Mature B‐cell lymphomas in adolescents and young adults. SHILAP Revista de lepidopterología. 4(4). 912–920.
7.
Belada, David, Kateřina Kopečková, Juan Bergua, et al.. (2023). Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study. Blood. 142(16). 1348–1358.
8.
Herrera, Alex F., Manish R. Patel, John M. Burke, et al.. (2022). Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. Clinical Cancer Research. 28(7). 1294–1301.
9.
Hlubocky, Fay J., Banu Symington, Daniel C. McFarland, et al.. (2021). Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organization’s Response for Readiness, Mitigation, and Resilience. JCO Oncology Practice. 17(7). 365–374.
10.
Danilov, Alexey V., Habte Yimer, Michael Boxer, et al.. (2021). Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine. Clinical Lymphoma Myeloma & Leukemia. 22(2). 121–128.
11.
Hlubocky, Fay J., Anthony L. Back, Tait D. Shanafelt, et al.. (2021). Occupational and Personal Consequences of the COVID-19 Pandemic on US Oncologist Burnout and Well-Being: A Study From the ASCO Clinician Well-Being Task Force. JCO Oncology Practice. 17(7). e427–e438.
12.
Younes, Anas, John M. Burke, Bruce D. Cheson, et al.. (2019). Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study. Blood. 134(Supplement_1). 2874–2874.
13.
Shah, Nirav N., Amrita Krishnan, Nina Shah, et al.. (2019). Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies. Blood. 134(Supplement_1). 5329–5329.
14.
Yimer, Habte, Jason M. Melear, Edward A. Faber, et al.. (2017). Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM). Blood. 130. 1839–1839.
15.
Grunwald, Michael R., John M. Burke, David J. Kuter, et al.. (2017). Patient-Reported Symptom Burden and Peripheral Blood Counts Among Patients with Polycythemia Vera: An Analysis from the Reveal Study. Blood. 130. 2924.
16.
Kahl, Brad S., John M. Burke, Richard van der Jagt, et al.. (2017). Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial. Blood. 130. 484–484.
17.
Sharman, Jeff P., Charles M. Farber, Daruka Mahadevan, et al.. (2016). Ublituximab ( TG ‐1101), a novel glycoengineered anti‐ CD 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. British Journal of Haematology. 176(3). 412–420.
18.
Flinn, Ian W., Richard van der Jagt, Brad S. Kahl, et al.. (2014). Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 123(19). 2944–2952.
19.
Burke, John M., et al.. (1997). Getting Physical: Excluding Personal Injury Awards under the New Section 104(a)(2). The Mathematics Enthusiast. 58(1). 7.
20.
Burke, John M.. (1974). Annexation in Montana -- A Time for Change. The Mathematics Enthusiast. 35(1). 5.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sandra Eloranta Breakdown of academic impact, for papers by Carrie A. Thompson Breakdown of academic impact, for papers by Grant W. Cannon Breakdown of academic impact, for papers by María A. López-Olivo Breakdown of academic impact, for papers by James D. Bearden Breakdown of academic impact, for papers by Helen K. Chew Breakdown of academic impact, for papers by Soo‐Mee Bang Breakdown of academic impact, for papers by Gerard Vreugdenhil Breakdown of academic impact, for papers by Marc Botteman Breakdown of academic impact, for papers by Laura Giordano